SOURCE: Spacelabs Healthcare

December 16, 2008 09:55 ET

Spacelabs Healthcare and Uscom Form Strategic Relationship for Distribution of Ultrasonic Cardiac Output Monitors

ISSAQUAH, WA and SYDNEY, AUSTRALIA--(Marketwire - December 16, 2008) - Spacelabs Healthcare and Uscom, Ltd. today signed a distribution agreement, giving Spacelabs exclusive distribution of the USCOM 1A ultrasonic cardiac output monitor in the Americas, Europe, Middle East, Africa and India.

The USCOM 1A offers real-time, beat-to-beat measurements of 20 parameters of cardiovascular function including cardiac output, stroke volume and systemic vascular resistance with additional parameters such as cardiac power, stroke work and oxygen delivery. This patent-protected monitor is completely non-invasive and validated across a wide range of cardiac outputs in neonates, infants, children and adults. Its custom-designed transducers use high fidelity continuous-wave Doppler technology to accurately measure cardiac flow.

"Uscom's ultrasonic cardiac output monitor is a logical complement to our comprehensive patient monitoring and diagnostic cardiology product offerings," said Joseph Davin, President of Spacelabs' North America Operations. "We are delighted with this opportunity to provide our customers with an additional tool for safe and rapid patient assessment, a further indication of our commitment to connecting innovation with care."

Uscom CEO, Paul Butler, said, "We are pleased to partner with Spacelabs Healthcare as they bring 50 years of service to healthcare providers and their patients to this relationship. This expanded distribution will increase delivery of Uscom's non-invasive, practice changing technology to the global market and further realize our ambition of providing improved care at lower cost and reduced risk."

About Spacelabs Healthcare, Inc.

Spacelabs Healthcare, Inc. (, a wholly-owned subsidiary of OSI Systems, Inc., is an international developer, manufacturer and distributor of medical equipment and services including solutions for patient monitoring and connectivity, anesthesia delivery and ventilation, diagnostic cardiology and supplies and accessories selling to hospitals, clinics and physician offices. Additionally, the Company provides centralized cardiac safety and diagnostic services (QT Studies, ECG, Holter, ABP, and Event Monitoring) to biopharmaceutical companies undertaking clinical trials. The Company has offices in the United States, United Kingdom, Canada, France, Germany, China, India and Singapore.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include information regarding the Company's expectations, goals or intentions about the future, including, but not limited to, statements regarding the contract with Uscom to distribute USCOM 1A monitors. The actual results may differ materially from those described in or implied by any forward-looking statement. Other important factors are set forth in the Securities and Exchange Commission filings of OSI Systems, Inc. All forward-looking statements speak only as of the date made, and we undertake no obligation to update these forward-looking statements.

About Uscom

Uscom Limited is an Australian medical device company, listed on the Australian Stock Exchange since December 2003. Uscom has developed a device for the safe and accurate measurement of cardiac output, a non-invasive alternative to the current invasive methods. Uscom offers a completely safe, painless and quick method of accurately measuring how well the heart is pumping. With its real-time beat-to-beat information across multiple parameters of cardiac function and advanced serial measurement capabilities, clinicians can accurately quantify the impact of therapy. The device is ideally suited to the Emergency Care setting where it is critical to monitor changes in cardiac output as fluids are applied. The Company has secured regulatory approval for sale of the Uscom Monitor in Australia, Europe and a number of Asian markets, including Japan, China and Taiwan. Uscom also has a CE Mark certification for Europe and a license from the State Food & Drug Administration for China. The Company received the necessary regulatory clearance for the United States market in February 2005 with the receipt of a 510K Pre Market Notification from the US Food & Drug Administration (FDA).

At Arab Health: Visit us at Hall 4, booth B30

At SCCM: Visit us at booths 216 and 218.

Contact Information